The Effect of Pain Catastrophizing on Acupuncture Treatment for Chronic Pain in Cancer Survivors.

J Pain Symptom ManageJun 17, 2026 (epub)
Clinical ResearchOncology (Medical)

Hyowoun Jyung, Lingyun Sun, Qing Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the influence of pain catastrophizing (PC) on acupuncture outcomes in 266 cancer survivors with chronic pain. Results indicated that patients with high baseline PC experienced greater reductions in pain severity (-3.9 vs. -2.1, P = 0.006) and pain interference (-3.8 vs. -2.6, P = 0.04) with electroacupuncture compared to those with low PC. Pain outcomes were not significantly affected in the battlefield acupuncture group.

Key findings

  • High PC patients receiving electroacupuncture had a pain severity reduction of -3.9 compared to -2.1 in low PC patients (P = 0.006).
  • Pain interference was reduced by -3.8 in high PC patients versus -2.6 in low PC patients receiving electroacupuncture (P = 0.04).
  • 83.3% of high PC patients in the electroacupuncture group were responders compared to 43.5% in the battlefield acupuncture group (P = 0.009).
  • No significant difference in responder rates was found between low PC patients in both acupuncture groups (66.1% vs. 64.5%, P = 0.8).

Why it matters

Understanding the role of pain catastrophizing in treatment outcomes can help clinicians tailor nonpharmacological interventions like acupuncture for cancer survivors, potentially improving pain management strategies.

Source

Published in J Pain Symptom Manage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.